Last reviewed · How we verify
RSVPreF3 OA investigational vaccine
RSVPreF3 OA investigational vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus in infants and young children. Also known as: Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine, RSVPreF3 OA.
RSVPreF3 OA investigational vaccine works by inducing an immune response against the respiratory syncytial virus.
RSVPreF3 OA investigational vaccine works by inducing an immune response against the respiratory syncytial virus. Used for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus in infants and young children.
At a glance
| Generic name | RSVPreF3 OA investigational vaccine |
|---|---|
| Also known as | Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine, RSVPreF3 OA |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a prefusion F protein, which is a key component of the RSV virus. By inducing an immune response against this protein, the vaccine aims to provide protection against RSV infection.
Approved indications
- Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus in infants and young children
Common side effects
- Injection site pain
Key clinical trials
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (PHASE3)
- A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease (PHASE3)
- A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older (PHASE3)
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above (PHASE3)
- A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) (PHASE3)
- A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above (PHASE3)
- A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (PHASE2)
- Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSVPreF3 OA investigational vaccine CI brief — competitive landscape report
- RSVPreF3 OA investigational vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about RSVPreF3 OA investigational vaccine
What is RSVPreF3 OA investigational vaccine?
How does RSVPreF3 OA investigational vaccine work?
What is RSVPreF3 OA investigational vaccine used for?
Who makes RSVPreF3 OA investigational vaccine?
Is RSVPreF3 OA investigational vaccine also known as anything else?
What development phase is RSVPreF3 OA investigational vaccine in?
What are the side effects of RSVPreF3 OA investigational vaccine?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus in infants and young children
- Also known as: Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine, RSVPreF3 OA
- Compare: RSVPreF3 OA investigational vaccine vs similar drugs
- Pricing: RSVPreF3 OA investigational vaccine cost, discount & access